Nu Skin Enterprises (NUS) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	001-12421
Entity Registrant Name	NU SKIN ENTERPRISES, INC.
Entity Central Index Key	0001021561
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0565309
Entity Address, Address Line One	75 West Center Street
Entity Address, City or Town	Provo
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84601
City Area Code	801
Local Phone Number	345-1000
Title of 12(b) Security	Class A Common Stock, $.001 par value
Trading Symbol	NUS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,711,020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 227,751	$ 256,057
Current investments	10,077	11,759
Accounts receivable, net	68,812	72,879
Inventories, net	247,789	279,978
Prepaid expenses and other	98,942	81,198
Total current assets	653,371	701,871
Property and equipment, net	410,673	432,965
Operating lease right-of-use assets	85,550	90,107
Goodwill	99,885	230,768
Other intangible assets, net	85,266	105,309
Other assets	248,150	245,443
Total assets	1,582,895	1,806,463
Current liabilities:
Accounts payable	32,736	43,505
Accrued expenses	246,615	260,366
Current portion of long-term debt	60,000	25,000
Total current liabilities	339,351	328,871
Operating lease liabilities	68,351	70,943
Long-term debt	373,470	478,040
Other liabilities	94,848	106,641
Total liabilities	876,020	984,495
Commitments and contingencies (Notes 5 and 11)
Stockholders' equity:
Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued	91	91
Additional paid-in capital	624,665	621,853
Treasury stock, at cost - 40.9 million and 41.1 million shares	(1,563,878)	(1,570,440)
Accumulated other comprehensive loss	(105,040)	(100,006)
Retained earnings	1,751,037	1,870,470
Total stockholders' equity	706,875	821,968
Total liabilities and stockholders' equity	$ 1,582,895	$ 1,806,463

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2024	Dec. 31, 2023
Stockholders' equity:
Common stock, shares authorized (in shares)	500	500
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	90.6	90.6
Treasury stock (in shares)	40.9	41.1

Consolidated Statements of Inco

Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Consolidated Statements of Income [Abstract]
Revenue	$ 430,145	$ 498,772	$ 1,286,532	$ 1,480,491
Cost of sales	128,682	206,505	383,828	475,635
Gross profit	301,463	292,267	902,704	1,004,856
Operating expenses:
Selling expenses	167,612	187,750	486,617	561,039
General and administrative expenses	115,620	130,882	358,107	401,825
Restructuring and impairment expenses	0	0	156,484	9,787
Total operating expenses	283,232	318,632	1,001,208	972,651
Operating income (loss)	18,231	(26,365)	(98,504)	32,205
Interest expense	6,500	7,535	20,545	18,192
Other income (expense), net	1,567	(551)	1,800	3,237
Income (loss) before provision for income taxes	13,298	(34,451)	(117,249)	17,250
Provision (benefit) for income taxes	4,996	2,504	(6,760)	15,937
Net income (loss)	$ 8,302	$ (36,955)	$ (110,489)	$ 1,313
Net income (loss) per share (Note 6):
Basic (in dollars per share)	$ 0.17	$ (0.74)	$ (2.23)	$ 0.03
Diluted (in dollars per share)	$ 0.17	$ (0.74)	$ (2.23)	$ 0.03
Weighted-average common shares outstanding:
Basic (in shares)	49,707	49,859	49,645	49,812
Diluted (in shares)	49,733	49,859	49,645	50,029

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Consolidated Statements of Comprehensive Income [Abstract]
Net income (loss)	$ 8,302	$ (36,955)	$ (110,489)	$ 1,313
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, net of taxes of zero for the three months ended September 30, 2024 and 2023, and zero and $(68) for the nine months ended September 30, 2024 and 2023, respectively	14,985	(6,518)	6	(20,196)
Net unrealized gains/(losses) on cash flow hedges, net of taxes of $262 and $(328) for the three months ended September 30, 2024 and 2023, respectively and $(325) and $(990) for the nine months ended September 30, 2024 and 2023, respectively	(949)	1,187	1,178	3,583
Reclassification adjustment for realized losses/(gains) in current earnings on cash flow hedges, net of taxes of $574 and $569 for the three months ended September 30, 2024 and 2023, respectively and $1,716 and $1,577 for the nine months ended September 30, 2024 and 2023, respectively	(2,081)	(2,059)	(6,218)	(5,714)
Other comprehensive income (loss), net of tax	11,955	(7,390)	(5,034)	(22,327)
Comprehensive income (loss)	$ 20,257	$ (44,345)	$ (115,523)	$ (21,014)

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, tax	$ 0	$ 0	$ 0	$ (68)
Net unrealized gains/(losses) on foreign currency cash flow hedges, tax	262	(328)	(325)	(990)
Reclassification adjustment for realized losses/(gains) in current earnings on cash flow hedges, tax	$ 574	$ 569	$ 1,716	$ 1,577

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member] Class A [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]	Total
Balance at beginning of period at Dec. 31, 2022	$ 91	$ 613,278	$ (1,569,061)	$ (86,509)	$ 1,939,497	$ 897,296
Stockholders' Equity [Roll Forward]
Net income (loss)	0	0	0	0	1,313	1,313
Other comprehensive income (loss), net of tax	0	0	0	(22,327)	0	(22,327)
Repurchase of Class A common stock (Note 6)	0	0	(13,011)	0	0	(13,011)
Exercise of employee stock options/vesting of stock awards	0	(6,613)	11,354	0	0	4,741
Stock-based compensation	0	12,528	0	0	0	12,528
Cash dividends	0	0	0	0	(58,353)	(58,353)
Balance at end of period at Sep. 30, 2023	91	619,193	(1,570,718)	(108,836)	1,882,457	822,187
Balance at beginning of period at Jun. 30, 2023	91	615,579	(1,557,777)	(101,446)	1,938,898	895,345
Stockholders' Equity [Roll Forward]
Net income (loss)	0	0	0	0	(36,955)	(36,955)
Other comprehensive income (loss), net of tax	0	0	0	(7,390)	0	(7,390)
Repurchase of Class A common stock (Note 6)	0	0	(13,011)	0	0	(13,011)
Exercise of employee stock options/vesting of stock awards	0	(111)	70	0	0	(41)
Stock-based compensation	0	3,725	0	0	0	3,725
Cash dividends	0	0	0	0	(19,486)	(19,486)
Balance at end of period at Sep. 30, 2023	91	619,193	(1,570,718)	(108,836)	1,882,457	822,187
Balance at beginning of period at Dec. 31, 2023	91	621,853	(1,570,440)	(100,006)	1,870,470	821,968
Stockholders' Equity [Roll Forward]
Net income (loss)	0	0	0	0	(110,489)	(110,489)
Other comprehensive income (loss), net of tax	0	0	0	(5,034)	0	(5,034)
Exercise of employee stock options/vesting of stock awards	0	(8,566)	6,562	0	0	(2,004)
Stock-based compensation	0	11,378	0	0	0	11,378
Cash dividends	0	0	0	0	(8,944)	(8,944)
Balance at end of period at Sep. 30, 2024	91	624,665	(1,563,878)	(105,040)	1,751,037	706,875
Balance at beginning of period at Jun. 30, 2024	91	621,440	(1,564,090)	(116,995)	1,745,718	686,164
Stockholders' Equity [Roll Forward]
Net income (loss)	0	0	0	0	8,302	8,302
Other comprehensive income (loss), net of tax	0	0	0	11,955	0	11,955
Exercise of employee stock options/vesting of stock awards	0	(265)	212	0	0	(53)
Stock-based compensation	0	3,490	0	0	0	3,490
Cash dividends	0	0	0	0	(2,983)	(2,983)
Balance at end of period at Sep. 30, 2024	$ 91	$ 624,665	$ (1,563,878)	$ (105,040)	$ 1,751,037	$ 706,875

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stockholders' Equity [Roll Forward]
Exercise of employee stock options (in shares)	0.1	0.1	0.3	0.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net (loss) income	$ (110,489)	$ 1,313
Adjustments to reconcile net (loss) income to cash flows from operating activities:
Impairment of goodwill, fixed assets and other intangibles	147,350	0
Depreciation and amortization	53,361	52,339
Non-cash lease expense	23,644	24,967
Stock-based compensation	11,378	12,528
Inventory write-down	5,104	83,642
Foreign currency losses	2,238	169
(Gain) loss on disposal of assets	(337)	626
Deferred taxes	(7,625)	(9,969)
Changes in operating assets and liabilities:
Accounts receivable, net	5,074	(27,829)
Inventories, net	24,948	(25,901)
Prepaid expenses and other	(21,174)	4,227
Other assets	(4,061)	(432)
Accounts payable	(10,556)	(4,667)
Accrued expenses	(19,032)	(43,062)
Other liabilities	(13,866)	(3,479)
Net cash provided by operating activities	85,957	64,472
Cash flows from investing activities:
Purchases of property and equipment	(29,000)	(38,105)
Proceeds on investment sales	18,378	13,160
Purchases of investments	(13,718)	(16,883)
Acquisitions (net of cash acquired)	0	(77,275)
Net cash used in investing activities	(24,340)	(119,103)
Cash flows from financing activities:
Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards	(2,004)	4,741
Payment of cash dividends	(8,944)	(58,353)
Repurchase of shares of common stock	0	(13,011)
Finance lease principal payments	(2,302)	(2,382)
Contingent consideration payments	(6,300)	0
Payments of debt	(85,000)	(10,000)
Proceeds from debt	15,000	110,000
Net cash (used in) / provided by financing activities	(89,550)	30,995
Effect of exchange rate changes on cash	(373)	(7,775)
Net decrease in cash and cash equivalents	(28,306)	(31,411)
Cash and cash equivalents, beginning of period	256,057	264,725
Cash and cash equivalents, end of period	$ 227,751	$ 233,314

The Company

The Company	9 Months Ended
	Sep. 30, 2024
The Company [Abstract]
The Company	1. The Company Nu Skin Enterprises, Inc. (the “Company”) is a holding company, with Nu Skin being the primary operating unit. Nu Skin develops and distributes premium-quality, innovative beauty and wellness products that are sold worldwide under the Nu Skin, Pharmanex and ageLOC brands and a small number of other products and services. The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments —Americas, , , Australia, New Zealand, and other markets; South Korea;

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information as of September and for the - and nine-month periods ended September 30, and The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. The consolidated balance sheet as of December has been prepared using information from the audited financial statements at that date. For further information, refer to the consolidated financial statements and accompanying footnotes included in the Company’s Annual Report on Form -K for the year ended December Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280). Reclassifications Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $7.5 million and $18.2 million of interest expense interest expense Inventory Inventories consist of the following (U.S. dollars in thousands): September 30, 2024 December 31, 2023 Raw materials $ 129,459 $ 140,133 Finished goods 118,330 139,845 Total Inventory, net $ 247,789 $ 279,978 Reserves of inventories consist of the following (U.S. dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Beginning balance $ 70,283 $ 41,017 $ 83,378 $ 37,267 Additions 1,584 68,563 5,104 83,642 Write-offs (8,359 ) (7,347 ) (24,974 ) (18,676 ) Ending Balance $ 63,508 $ 102,233 $ 63,508 $ 102,233 Revenue Recognition Contract Liabilities – Customer Loyalty Programs Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products. The balance of deferred revenue related to contract liabilities as of September and December was and , respectively. The contract liabilities impact to revenue for the -month periods ended September and was an increase of vely. T he impact to revenue for the nine-month periods ended September 30, 2024, and 2023 was an increase of $1.1 million and an increase of $6.8 million, respectively.

Goodwill and Intangibles

Goodwill and Intangibles	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangibles [Abstract]
Goodwill and Intangibles	3. Goodwill and Intangibles Goodwill The Company’s reporting units for goodwill are its operating segments, which are also its reportable segments, with the exception of Rhyz other. The Rhyz other segment is made up of three During the three months ended June 30, 2024, the Company determined that the continued decline in the Company’s stock price and corresponding market capitalization as well as declines in some of the Company’s reporting units’ forecasts were triggering events that required the Company to perform a quantitative impairment analysis for all reporting units. Based on the analysis, the Company concluded the fair values of certain of its reporting units were less than their carrying values. As a result, the Company recorded non-cash goodwill impairment charges of $130.9 million within restructuring and impairment expenses on the consolidated statement of income during the three months ended June 30, 2024. The impairment charges were $9.4 million for the Americas segment, $32.2 million for the Mainland China segment, $18.5 million for the Southeast Asia/Pacific segment, $16.0 million for the Japan segment, $29.3 million for the South Korea segment, $2.9 million for the Europe & Africa segment, $6.6 million for the Hong Kong/Taiwan segment and $15.9 million for the BeautyBio reporting unit within the Rhyz other segment. As part of the Company’s impairment analysis, the fair values of the reporting units were determined using the income approach. The income approach used level 3 inputs and utilized management estimates related to revenue growth rates, profitability margins, estimated future cash flows and discount rates. During the three months ended September 30, 2024, the Company determined that the continued decline in the Company’s stock price and corresponding market capitalization was a triggering event that required the Company to perform a quantitative impairment analysis for the Manufacturing and Rhyz other reporting units. Based on the analysis, the Company concluded the fair value of the Manufacturing and Rhyz other reporting units were in excess of their carrying amounts and no impairment charge was required. For goodwill, the estimated fair value of Manufacturing and Rhyz other reporting units exceeded the carrying value by approximately 2% - 8%; therefore, the reporting units are considered to be at risk of future impairment. The Manufacturing and Rhyz other reporting units’ fair values remain sensitive to unfavorable changes in assumptions utilized in the income approach, including revenue growth rates, profitability margins, estimated future cash flows, and the discount rates that could result in impairment charges in a future period. The following table presents goodwill allocated to the Company’s reportable segments for the periods ended and December 31, 2023 (U.S. dollars in thousands): September 30, 2024 December 31, 2023 Nu Skin Americas $ — $ 9,449 Southeast Asia/Pacific — 18,537 Mainland China — 32,179 Japan — 16,019 South Korea — 29,261 Europe & Africa — 2,875 Hong Kong/Taiwan — 6,634 Rhyz Investments Manufacturing 78,875 78,875 Rhyz other 21,010 36,939 Total $ 99,885 $ 230,768 Accumulated impairment charges as of September 30, 2024 were $9.4 million for the Americas segment, $18.5 million for the Southeast Asia/Pacific segment, Intangibles The Company reviews long-lived assets for impairment when performance expectations, events or change in circumstances indicate that the assets’ carrying value may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows by comparing the carrying value of the asset group to the net undiscounted cash flows. If the evaluation indicates that the carrying amount of the assets may not be recoverable, any potential impairment is measured based upon the fair value of the related asset group. During the second quarter of 2024, based on continued losses and change in forecasted losses associated with the BeautyBio retail asset group within the Rhyz other segment, the Company concluded that these factors were an interim triggering event. As a result, the Company performed an interim impairment test of the asset group and assessed the recoverability of the related asset group by comparing the carrying value of the retail asset group to the net undiscounted cash flow expected to be generated. The recoverability test indicated that the retail asset group was impaired. The Company concluded the retail asset group’s carrying value exceeded its estimated fair value, which was determined utilizing the discounted projected future cash flows, which resulted in an impairment charge. The estimated fair value was based on expected future cash flows using level 3 inputs and utilized management estimates related to revenue growth rates, profitability margins and discount rates. The Company recorded an impairment charge of $10.1 million for its Rhyz other segment during the three months ended June 30, 2024 within restructuring and impairment expenses on the consolidated statement of income. The retail asset group has a remaining carrying value of $2.3 million with a remaining amortization period of approximately 9 years.

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt [Abstract]
Debt	4. Debt Credit Agreement On June 14, 2022, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with several financial institutions as lenders and Bank of America, N.A., as administrative agent, which amended and restated the 2018 Credit Agreement. The Credit Agreement provides for a $400 million term loan facility and a $500 million revolving credit facility, each with a term of five years. Both facilities bear interest at the SOFR, plus a margin based on the Company’s consolidated leverage ratio. Commitment fees payable under the Credit Agreement are also based on the consolidated leverage ratio as defined in the Credit Agreement and range from 0.175% to 0.30% on the unused portion of the total lender commitments then in effect. The term loan facility amortizes in quarterly installments in amounts resulting in an annual amortization of 2.5% during the first year and 5.0% during the second, third, fourth and fifth years after the closing date of the Credit Agreement, with the remainder payable at final maturity. The Credit Agreement is guaranteed by certain of the Company’s domestic subsidiaries and collateralized by assets of such subsidiaries, including a pledge of 65% of the capital stock of certain foreign subsidiaries. The Credit Agreement requires the Company to maintain a consolidated leverage ratio not exceeding 2.75 to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. As of September 30, 2024, the Company was in compliance with all covenants under the Credit Agreement. The following table summarizes the Company’s debt facilities as of September 30, 2024 and December 31, 2023: Facility or Arrangement Original Principal Amount Balance as of September 30, 2024 (1)(2) Balance as of December 31, 2023 (1)(2) Interest Rate Repayment Terms Credit Agreement term loan facility $400.0 million $365.0 million $385.0 million Variable 21% of the principal amount is payable Credit Agreement revolving credit facility $70.0 million $120.0 million Variable Revolving line of credit expires June 14, 2027. (1) As of September 30, 2024 and December 31, 2023, the current portion of the Company’s debt (i.e., becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $40.0 million and zero, respectively, of the balance under the revolving line of credit. (2) The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.5 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	5. Leases As of . The components of lease expense were as follows (U.S. dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease expense Operating lease cost $ 5,953 $ 6,762 $ 17,892 $ 22,945 Variable lease cost 1,961 1,923 4,701 3,410 Finance lease expense Amortization of right-of-use assets 700 1,240 2,183 3,843 Interest on lease liabilities 86 123 289 380 Total lease expense $ 8,700 $ 10,048 $ 25,065 $ 30,578 Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands): Nine Months Ended September 30, 2024 2023 Operating cash outflow from operating leases $ 19,103 $ 21,975 Operating cash outflow from finance leases $ 295 $ 360 Financing cash outflow from finance leases $ 2,302 $ 2,382 Right-of-use assets obtained in exchange for operating lease obligations $ 14,914 $ 14,351 Right-of-use assets obtained in exchange for finance lease obligations $ 10 $ 782 Maturities of lease liabilities were as follows (U.S. dollars in thousands): Year Ending December 31 Operating Leases Finance Leases 2024 $ 6,371 $ 733 2025 21,164 2,822 2026 16,202 2,817 2027 12,304 2,795 2028 9,112 736 Thereafter 32,953 — Total 98,106 9,903 Less: Finance charges 10,072 612 Total principal liability $ 88,034 $ 9,291 The Company has additional lease liabilities of $0.1 million which have not yet commenced as of September 30, 2024, and as such, have not been recognized on the consolidated balance sheets.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2024
Capital Stock [Abstract]
Capital Stock	6. Capital Stock Net income per share Net income per share is computed based on the weighted-average number of common shares outstanding during the periods presented. Additionally, diluted earnings per share data gives effect to all potentially dilutive common shares that were outstanding during the periods presented. For the three-month periods ended September 30, 2024 and 2023, stock options of million and 2.1 million, respectively, and for the nine-month periods ended September 30, 2024 and 2023, stock options of million and million, respectively, were excluded from the calculation of diluted earnings per share because they were anti-dilutive. Dividends In February May August 2024 November 2024 Repurchase of common stock During the three- and nine-month periods ended September 30, 2024, the Company repurchased zero shares of its Class A common stock under its stock repurchase plan. As of September 30, 2024, $162.4 million was available for repurchases under the Company’s stock repurchase plan.

Fair Value and Equity Investmen

Fair Value and Equity Investments	9 Months Ended
	Sep. 30, 2024
Fair Value and Equity Investments [Abstract]
Fair Value and Equity Investments	7. Fair Value and Equity Investments Fair Value The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximates fair values due to the short-term nature of these instruments. The carrying value of debt approximates fair value due to the variable 30-day interest rate. Fair value estimates are made at a specific point in time, based on relevant market information. The FASB Codification defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. On a quarterly basis, the Company measures at fair value certain financial assets, including cash equivalents. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair-value hierarchy: ■ Level 1 – quoted prices in active markets for identical assets or liabilities; ■ Level 2 – inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and ■ Level 3 – unobservable inputs based on the Company’s own assumptions. Accounting standards permit companies, at their option, to measure certain financial instruments and other eligible items at fair value. The Company has elected not to apply the fair value option to existing eligible items beyond what is required by US GAAP. The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in thousands): Fair Value at September 30, 2024 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 29,539 $ — $ — $ 29,539 Derivative financial instruments asset — 6,258 — 6,258 Life insurance contracts — — 43,994 43,994 Contingent consideration — — — — Total $ 29,539 $ 6,258 $ 43,994 $ 79,791 Fair Value at December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 42,916 $ — $ — $ 42,916 Derivative financial instruments asset — 12,689 — 12,689 Life insurance contracts — — 45,041 45,041 Contingent consideration — — (6,300 ) (6,300 ) Total $ 42,916 $ 12,689 $ 38,741 $ 94,346 The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ 45,041 $ 40,055 Actual return on plan assets 6,153 2,341 Sales and settlements (7,200 ) (483 ) Ending balance at September 30 $ 43,994 $ 41,913 Life insurance contracts: The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ (6,300 ) $ (6,364 ) Changes in fair value of contingent consideration — (58 ) Payments 6,300 — Ending balance at September 30 $ — $ (6,422 ) Contingent consideration: Equity Investments The Company maintains equity investments in companies which are accounted for under the measurement alternative described in ASC - - - for equity securities that lack readily determinable fair values. The carrying amount of equity securities held by the Company without readily determinable fair values was at each of September 30, 2024 and December During the months ended September the Company recognized upward fair value adjustments, based on the valuation of additional equity issued by the investee which was deemed to be an observable transaction of a similar investment under ASC was recorded within Other income (expense), net on the Consolidated Statement of Income. The upward fair value adjustment represents a nonrecurring fair value measurement based on observable price changes and is classified as a Level fair value measurement.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
Income Taxes	8. Income Taxes Provision (benefit) for income taxes for the three- and nine-month periods ended September 30, 2024 was $5.0 million and $(6.8) million, compared to $2.5 million and $15.9 million for the prior-year periods. The effective tax rates for the three- and nine-month periods ended September The Company accounts for income taxes in accordance with ASC Topic 740 “Income Taxes.” These standards establish financial accounting and reporting standards for the effects of income taxes that result from an enterprise’s activities during the current and preceding years. The Company takes an asset and liability approach for financial accounting and reporting of income taxes. The Company pays income taxes in many foreign jurisdictions based on the profits realized in those jurisdictions, which can be significantly impacted by terms of intercompany transactions between the Company and its foreign affiliates. Deferred tax assets and liabilities are created in this process. The Company has netted these deferred tax assets and deferred tax liabilities by jurisdiction. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company had net deferred tax assets of $115.3 million and $105.0 million as of September The Company evaluates its indefinite reinvestment assertions with respect to foreign earnings for each quarter. For all foreign earnings, the Company accrues the applicable foreign income taxes. For the earnings that have been indefinitely reinvested, the Company does not accrue foreign withholding taxes. Undistributed earnings that the Company has indefinitely reinvested, for which no foreign withholding taxes have been provided, aggregate to $60.0 million as of December 31, 2023. If the amount designated as indefinitely reinvested as of December 31, 2023 were repatriated to the United States, the amount of incremental taxes would be approximately $6.0 million. The Company intends to utilize the indefinitely reinvested offshore earnings to fund foreign investments, specifically capital expenditures. The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. In 2009, the Company entered into a voluntary program with the IRS called Compliance Assurance Process (“CAP”). The objective of CAP is to contemporaneously work with the IRS to achieve federal tax compliance and resolve all or most of the issues prior to filing of the tax return. As of December 31, 2023, tax years through 2020 and 2022 have been audited and are effectively closed to further examination. For tax year 2021, the Company was in the Bridge phase of the CAP program, pursuant to which the IRS will not accept disclosures, will not conduct reviews and will not provide letters of assurance for the Bridge years. There are limited circumstances that tax years in the Bridge phase will be opened for examination. For tax years 2023 and 2024, the Company has been accepted in the IRS’s Bridge Plus program. The Company may elect to continue participating in CAP for future tax years; the Company may withdraw from the program at any time. With a few exceptions, the Company is no longer subject to state and local income tax examination by tax authorities for the years before 2020. Foreign jurisdictions have varying lengths of statutes of limitations for income tax examinations. Some statutes are as short as three years and in certain markets may be as long as ten years. The Company is currently under examination in certain foreign jurisdictions; however, the outcomes of those reviews are not yet determinable. The Company’s unrecognized tax benefits relate to multiple jurisdictions. Due to potential increases in unrecognized tax benefits from the multiple jurisdictions in which the Company operates, as well as the expiration of various statutes of limitations, it is reasonably possible that the Company’s gross unrecognized tax benefits, net of foreign currency adjustments, may decrease in the next 12 months by approximately $3.0 to $4.0 million. In 2021, as part of the Organization for Economic Co-operation and Development’s (“OECD”) Inclusive Framework, 140 member countries agreed to the implementation of the Pillar Two Global Minimum Tax (“Pillar Two”) of 15%. The OECD continues to release additional guidance, including administrative guidance on how Pillar Two rules should be interpreted and applied by jurisdictions as they adopt Pillar Two. A number of countries have utilized the administrative guidance as a starting point for legislation that went into effect January 1, 2024. Based on current enacted legislation, the Company anticipates the impact of Pillar Two to be immaterial for 2024.

Derivatives and Hedging Activit

Derivatives and Hedging Activities	9 Months Ended
	Sep. 30, 2024
Derivatives and Hedging Activities [Abstract]
Derivatives and Hedging Activities	9. Derivatives and Hedging Activities Risk Management Objective of Using Derivatives The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings. Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2024, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt. For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income and subsequently reclassified into interest expense/income in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense/income as interest payments are made/received on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an additional $6.3 million will be reclassified as a reduction to interest expense. As of September 30, 2024 and December 31, 2023, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk with a total notional amount of $200 million. Fair Values of Derivative Instruments on the Balance Sheet The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet: Fair Values of Derivative Instruments Derivatives in Cash flow Hedging Relationships: Balance Sheet Location September 30, 2024 December 31, 2023 Interest Rate Swap - Asset Prepaid expenses and other $ 6,258 $ 8,955 Interest Rate Swap - Asset Other assets $ — $ 3,734 Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss. Amount of Gain (Loss) Recognized in Other Comprehensive Loss on Derivatives Three Months Ended Nine Months Ended September 30, September 30, Derivatives in Cash flow Hedging Relationships: 2024 2023 2024 2023 Interest Rate Swaps $ (1,211 ) $ 1,515 $ 1,503 $ 4,573 Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income Three Months Ended Nine Months Ended September 30, September 30, Derivatives in Cash flow Hedging Relationships: Income Statement Location 2024 2023 2024 2023 Interest Rate Swaps Other expense, net $ 2,655 $ 2,628 $ 7,934 $ 7,291

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2024
Segment Information [Abstract]
Segment Information	10. Segment Information The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments—Americas, Mainland China, Southeast Asia/Pacific, South Korea, Japan, Europe & Africa Profitability by segment as determined under US GAAP is driven primarily by the Company’s transfer pricing policies. Segment contribution, which is the Company’s segment profitability metric presented in the table below, excludes certain intercompany charges, specifically royalties, license fees, transfer pricing, discrete charges and other miscellaneous items. These charges have been included in Corporate and other expenses. Corporate and other expenses also include costs related to the Company’s executive and administrative offices, information technology, research and development, and marketing and supply chain functions not recorded at the segment level. The accounting policies of the segments are the same as those described in Note 2 – Summary of Significant Accounting Policies. The Company evaluates the performance of its segments based on revenue and segment contribution. Each segment records direct expenses related to its employees and its operations. Summarized financial information for the Company’s reportable segments is shown in the following tables. Asset information is not reviewed or included with the Company’s internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment. Revenue by Segment Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 77,194 $ 91,671 $ 237,160 $ 300,469 Southeast Asia/Pacific 59,515 68,743 179,921 200,317 Mainland China 53,020 70,225 178,797 226,563 Japan 47,222 53,399 134,045 156,867 South Korea 45,201 63,709 130,283 187,719 Europe & Africa 38,577 50,048 121,564 144,460 Hong Kong/Taiwan 33,749 40,724 98,061 112,380 Nu Skin other 2,518 (274 ) 3,186 208 Total Nu Skin 356,996 438,245 1,083,017 1,328,983 Rhyz Investments Manufacturing (1) 51,773 49,714 153,548 131,032 Rhyz other 21,376 10,813 49,967 20,476 Total Rhyz Investments 73,149 60,527 203,515 151,508 Total $ 430,145 $ 498,772 $ 1,286,532 $ 1,480,491 (1) The . Segment Contribution Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 15,881 $ 16,627 $ 48,236 $ 61,730 Southeast Asia/Pacific 9,997 13,190 31,787 37,057 Mainland China 7,277 15,223 32,903 48,192 Japan 13,491 14,617 37,201 40,033 South Korea 14,283 19,433 39,789 60,399 Europe & Africa 5,193 6,562 13,874 15,145 Hong Kong/Taiwan 9,225 10,146 25,006 28,128 Nu Skin contribution 75,347 95,798 228,796 290,684 Rhyz Investments Manufacturing 542 4,838 4,266 7,683 Rhyz other (2,923 ) (5,966 ) (14,338 ) (11,318 ) Rhyz Investments contribution (2,381 ) (1,128 ) (10,072 ) (3,635 ) Total segment contribution 72,966 94,670 218,724 287,049 Corporate and other (54,735 ) (121,035 ) (317,228 ) (254,844 ) Operating income 18,231 (26,365 ) (98,504 ) 32,205 Interest expense 6,500 7,535 20,545 18,192 Other income, net 1,567 (551 ) 1,800 3,237 Income (loss) before provision for income taxes $ 13,298 $ (34,451 ) $ (117,249 ) $ 17,250 Depreciation and Amortization Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 85 $ 115 $ 283 $ 307 Southeast Asia/Pacific 227 257 650 813 Mainland China 2,697 2,742 8,197 8,127 Japan 65 93 217 1,241 South Korea 256 310 762 1,062 Europe & Africa 283 271 830 810 Hong Kong/Taiwan 451 715 1,348 1,990 Total Nu Skin 4,064 4,503 12,287 14,350 Rhyz Investments Manufacturing 3,460 3,297 10,227 10,050 Rhyz other 1,679 2,048 5,531 3,816 Total Rhyz Investments 5,139 5,345 15,758 13,866 Corporate and other 8,118 8,344 25,316 24,123 Total $ 17,321 $ 18,192 $ 53,361 $ 52,339 Capital Expenditures Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 38 $ 18 $ 71 $ 209 Southeast Asia/Pacific 7 130 25 321 Mainland China 690 3,496 4,957 12,265 Japan 101 81 122 84 South Korea 7 361 29 522 Europe & Africa 97 46 386 322 Hong Kong/Taiwan 174 90 410 698 Total Nu Skin 1,114 4,222 6,000 14,421 Rhyz Investments Manufacturing 1,209 2,621 3,673 8,318 Rhyz other 490 20 1,559 20 Total Rhyz Investments 1,699 2,641 5,232 8,338 Corporate and other 5,783 5,043 17,768 15,346 Total $ 8,596 $ 11,906 $ 29,000 $ 38,105

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is subject to government regulations pertaining to product formulation, labeling and packaging, product claims and advertising, and the Company’s direct selling system. The Company is also subject to the jurisdiction of numerous foreign tax and customs authorities. Any assertions or determination that either the Company or the Company’s sales force is not in compliance with existing statutes, laws, rules or regulations could have a material adverse effect on the Company’s operations. In addition, in any country or jurisdiction, the adoption of new statutes, laws, rules or regulations or changes in the interpretation of existing statutes, laws, rules or regulations could have a material adverse effect on the Company and its operations. No assurance can be given that the Company’s compliance with applicable statutes, laws, rules and regulations will not be challenged by foreign authorities or that such challenges will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company and its Subsidiaries are defendants in litigation, investigations and other proceedings involving various matters. Management believes that the ultimate liability arising from such claims and contingencies, if any, is not likely to have a material adverse effect on the Company’s consolidated financial condition, results of operations or cash flows. The Company is subject to regular audits by federal, state and foreign tax authorities. These audits may result in additional tax liabilities. The Company believes it has appropriately provided for income taxes for all years. Several factors drive the calculation of its tax reserves. Some of these factors include: (i) the expiration of various statutes of limitations; (ii) changes in tax law and regulations; (iii) issuance of tax rulings; and (iv) settlements with tax authorities. Changes in any of these factors may result in adjustments to the Company’s reserves, which would impact its reported financial results.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2024
Acquisitions [Abstract]
Acquisitions	12. Acquisitions In April 2023, the Company acquired 60 percent of LifeDNA, Inc. (“LifeDNA”), a DNA assessment company. Consideration paid included $4.0 million of cash, along with the conversion of a previous $3.0 million Simple Agreement for Future Equity (“SAFE”), and a $0.2 million convertible note. The acquisition enables the Company to continue to expand its digital tools. The Company allocated the fair value of $12.0 million to the assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $7.3 million of intangible assets, $1.7 million of cash, $0.1 million of current assets, $0.9 million of accrued liabilities and also resulted in a deferred tax liability of $0.9 million. The excess purchase price over the aggregate fair value of assets acquired less liabilities assumed of $4.7 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected synergies. None of the goodwill is expected to be deductible for income tax purposes. The intangible assets acquired comprised $0.6 million of customer relationships, $1.7 million of technology, $1.0 million of tradenames and $4.1 million of other intangibles. The intangibles were assigned useful lives of 7 years for the technology, tradenames and other intangibles, and 2 years for the customer relationships. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $1.1 million to deferred tax liability and goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three months ended December 31, 2023. In June 2023, the Company acquired 100 percent ownership in Beauty Biosciences, LLC (“BeautyBio”), making BeautyBio a wholly owned subsidiary of the Company. The acquisition expands the Company’s product and device offerings within its Rhyz segment. The purchase price for BeautyBio was $75.0 million, net of cash acquired of $1.5 million, all payable in cash. The Company allocated the gross purchase price of $76.5 million to the assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $43.0 million of intangible assets, $1.5 million of cash, $3.5 million of accounts receivable, $10.3 million of inventory, $0.8 million of prepaid and other assets, $1.0 million of fixed assets, $1.2 million of an ROU operating lease asset and corresponding lease liability, $2.5 million of accounts payable and accrued liabilities and also resulted in a deferred tax liability of $0.7 million. The excess purchase price over the aggregate fair value of assets acquired less liabilities assumed of $19.6 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected synergies. None of the goodwill is expected to be deductible for income tax purposes. The intangible assets acquired comprised $18.4 million of customer relationships, $2.3 million of technology, $20.9 million of tradenames and $1.4 million of other intangibles. The intangibles were assigned useful lives of approximately 19 years for the technology and tradenames, approximately 9 years for the customer relationships and 3 years for the other intangibles. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $(1.2) million to accounts receivable, $(0.7) million of inventory, $(0.5) million of accrued liabilities, $0.7 million of deferred tax liability, $(0.3) of intangible assets and $2.4 million of goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three months ended March 31, 2024. The financial results of LifeDNA and BeautyBio are included in the Rhyz other segment from the date of acquisition. For the three and nine months ended September 30, 2024, the Company included $3.0 million and $12.6 million, respectively, of revenue from these acquisitions. The unaudited pro forma revenue for the Company, including LifeDNA and BeautyBio, as if the acquisitions occurred on January 1, 2023, would have been $1,489.1 million for the nine months ended September 30, 2023, respectively.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2024
Restructuring [Abstract]
Restructuring	13. Restructuring In the third quarter of 2022, the Company adopted a strategic plan (“2022 Plan”) to focus resources on the Company’s strategic priorities and optimize future growth and profitability. The global program includes workforce reductions and footprint optimization. The Company incurred total charges under the program of approximately $53.3 million, with $40.8 million in cash charges of severance and lease termination cost and approximately $12.5 million of non-cash charges of impairment of fixed assets, acceleration of depreciation and impairment of other intangibles related to the footprint optimization. During 2022, the Company incurred charges to be settled in cash of $20.1 million in severance charges, $7.4 million in lease termination cost, and $5.2 million in other associated cost, and non-cash charges of $8.2 million in fixed asset impairments, $0.9 million in accelerated depreciation and $1.7 million in impairment of other intangibles. During 2022, the Company made cash payments of $21.0 million related to this global program, leaving an ending restructuring accrual of $11.7 million. During the first quarter and full year of 2023, the Company incurred charges to be settled in cash of $4.0 million in severance charges, $1.9 million in lease termination cost, and $2.2 million in other associated cost, and non-cash charges of $1.7 million in accelerated depreciation. In 2023, the Company made cash payments of $19.8 million, leaving no restructuring accrual related to this plan as of December 31, 2023. Restructuring expense by segment - 2022 Plan (U.S. dollars in thousands) Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total Nu Skin Americas $ 918 $ 1,687 $ 2,605 Southeast Asia/Pacific 131 1,809 1,940 Mainland China 1,352 13,181 14,533 Japan 1,515 699 2,214 South Korea 422 1,533 1,955 Europe & Africa (113 ) 2,143 2,030 Hong Kong/Taiwan (201 ) 2,464 2,263 Total Nu Skin 4,024 23,516 27,540 Rhyz Investments Manufacturing 13 401 414 Rhyz other — — — Total Rhyz Investments 13 401 414 Corporate and other 5,750 19,577 25,327 Total $ 9,787 $ 43,494 $ 53,281 In the fourth quarter of 2023, the Company adopted another strategic plan (“2023 Plan”) to focus resources on the Company’s global priorities and optimize future growth and profitability. The global program includes workforce reductions. The Company estimates total charges under the program will approximate $30 – R Three Months Ended (U.S. dollars in thousands) June 30, 2024 March 31, 2024 December 31, 2023 Total Nu Skin Americas $ 267 $ 3,145 $ 598 $ 4,010 Southeast Asia/Pacific 190 307 862 1,359 Mainland China (162 ) 1,017 2,910 3,765 Japan — 24 — 24 South Korea (134 ) 134 — — Europe & Africa 414 677 554 1,645 Hong Kong/Taiwan (147 ) 357 432 642 Total Nu Skin 428 5,661 5,356 11,445 Rhyz Investments Manufacturing — — — — Rhyz other 40 — — 40 Total Rhyz Investments 40 — — 40 Corporate and other 7,896 1,473 4,647 14,016 Total $ 8,364 $ 7,134 $ 10,003 $ 25,501

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Accounting	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”)
Consolidation	The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Accounting Pronouncements	Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280).
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $7.5 million and $18.2 million of interest expense interest expense
Revenue Recognition	Revenue Recognition Contract Liabilities – Customer Loyalty Programs Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products. The balance of deferred revenue related to contract liabilities as of September and December was and , respectively. The contract liabilities impact to revenue for the -month periods ended September and was an increase of vely. T he impact to revenue for the nine-month periods ended September 30, 2024, and 2023 was an increase of $1.1 million and an increase of $6.8 million, respectively.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Inventories	Inventories consist of the following (U.S. dollars in thousands): September 30, 2024 December 31, 2023 Raw materials $ 129,459 $ 140,133 Finished goods 118,330 139,845 Total Inventory, net $ 247,789 $ 279,978
Inventory Reserves	Reserves of inventories consist of the following (U.S. dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Beginning balance $ 70,283 $ 41,017 $ 83,378 $ 37,267 Additions 1,584 68,563 5,104 83,642 Write-offs (8,359 ) (7,347 ) (24,974 ) (18,676 ) Ending Balance $ 63,508 $ 102,233 $ 63,508 $ 102,233

Goodwill and Intangibles (Table

Goodwill and Intangibles (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangibles [Abstract]
Goodwill	The following table presents goodwill allocated to the Company’s reportable segments for the periods ended and December 31, 2023 (U.S. dollars in thousands): September 30, 2024 December 31, 2023 Nu Skin Americas $ — $ 9,449 Southeast Asia/Pacific — 18,537 Mainland China — 32,179 Japan — 16,019 South Korea — 29,261 Europe & Africa — 2,875 Hong Kong/Taiwan — 6,634 Rhyz Investments Manufacturing 78,875 78,875 Rhyz other 21,010 36,939 Total $ 99,885 $ 230,768

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt [Abstract]
Debt Facilities	The following table summarizes the Company’s debt facilities as of September 30, 2024 and December 31, 2023: Facility or Arrangement Original Principal Amount Balance as of September 30, 2024 (1)(2) Balance as of December 31, 2023 (1)(2) Interest Rate Repayment Terms Credit Agreement term loan facility $400.0 million $365.0 million $385.0 million Variable 21% of the principal amount is payable Credit Agreement revolving credit facility $70.0 million $120.0 million Variable Revolving line of credit expires June 14, 2027. (1) As of September 30, 2024 and December 31, 2023, the current portion of the Company’s debt (i.e., becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $40.0 million and zero, respectively, of the balance under the revolving line of credit. (2) The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.5 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Components of Lease Expense	The components of lease expense were as follows (U.S. dollars in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease expense Operating lease cost $ 5,953 $ 6,762 $ 17,892 $ 22,945 Variable lease cost 1,961 1,923 4,701 3,410 Finance lease expense Amortization of right-of-use assets 700 1,240 2,183 3,843 Interest on lease liabilities 86 123 289 380 Total lease expense $ 8,700 $ 10,048 $ 25,065 $ 30,578
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands): Nine Months Ended September 30, 2024 2023 Operating cash outflow from operating leases $ 19,103 $ 21,975 Operating cash outflow from finance leases $ 295 $ 360 Financing cash outflow from finance leases $ 2,302 $ 2,382 Right-of-use assets obtained in exchange for operating lease obligations $ 14,914 $ 14,351 Right-of-use assets obtained in exchange for finance lease obligations $ 10 $ 782
Maturities of Lease Liabilities	Maturities of lease liabilities were as follows (U.S. dollars in thousands): Year Ending December 31 Operating Leases Finance Leases 2024 $ 6,371 $ 733 2025 21,164 2,822 2026 16,202 2,817 2027 12,304 2,795 2028 9,112 736 Thereafter 32,953 — Total 98,106 9,903 Less: Finance charges 10,072 612 Total principal liability $ 88,034 $ 9,291

Fair Value and Equity Investm_2

Fair Value and Equity Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value and Equity Investments [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in thousands): Fair Value at September 30, 2024 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 29,539 $ — $ — $ 29,539 Derivative financial instruments asset — 6,258 — 6,258 Life insurance contracts — — 43,994 43,994 Contingent consideration — — — — Total $ 29,539 $ 6,258 $ 43,994 $ 79,791 Fair Value at December 31, 2023 Level 1 Level 2 Level 3 Total Financial assets (liabilities): Cash equivalents and current investments $ 42,916 $ — $ — $ 42,916 Derivative financial instruments asset — 12,689 — 12,689 Life insurance contracts — — 45,041 45,041 Contingent consideration — — (6,300 ) (6,300 ) Total $ 42,916 $ 12,689 $ 38,741 $ 94,346
Changes in Fair Value of Level 3 Life Insurance Contracts	The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ 45,041 $ 40,055 Actual return on plan assets 6,153 2,341 Sales and settlements (7,200 ) (483 ) Ending balance at September 30 $ 43,994 $ 41,913
Changes in Fair Value of Level 3 Contingent Consideration	The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands): 2024 2023 Beginning balance at January 1 $ (6,300 ) $ (6,364 ) Changes in fair value of contingent consideration — (58 ) Payments 6,300 — Ending balance at September 30 $ — $ (6,422 )

Derivatives and Hedging Activ_2

Derivatives and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2024
Derivatives and Hedging Activities [Abstract]
Fair Value of Derivative Instruments on the Balance Sheet	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet: Fair Values of Derivative Instruments Derivatives in Cash flow Hedging Relationships: Balance Sheet Location September 30, 2024 December 31, 2023 Interest Rate Swap - Asset Prepaid expenses and other $ 6,258 $ 8,955 Interest Rate Swap - Asset Other assets $ — $ 3,734
Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss	The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss. Amount of Gain (Loss) Recognized in Other Comprehensive Loss on Derivatives Three Months Ended Nine Months Ended September 30, September 30, Derivatives in Cash flow Hedging Relationships: 2024 2023 2024 2023 Interest Rate Swaps $ (1,211 ) $ 1,515 $ 1,503 $ 4,573 Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income Three Months Ended Nine Months Ended September 30, September 30, Derivatives in Cash flow Hedging Relationships: Income Statement Location 2024 2023 2024 2023 Interest Rate Swaps Other expense, net $ 2,655 $ 2,628 $ 7,934 $ 7,291

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Information [Abstract]
Revenue by Segment	Revenue by Segment Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 77,194 $ 91,671 $ 237,160 $ 300,469 Southeast Asia/Pacific 59,515 68,743 179,921 200,317 Mainland China 53,020 70,225 178,797 226,563 Japan 47,222 53,399 134,045 156,867 South Korea 45,201 63,709 130,283 187,719 Europe & Africa 38,577 50,048 121,564 144,460 Hong Kong/Taiwan 33,749 40,724 98,061 112,380 Nu Skin other 2,518 (274 ) 3,186 208 Total Nu Skin 356,996 438,245 1,083,017 1,328,983 Rhyz Investments Manufacturing (1) 51,773 49,714 153,548 131,032 Rhyz other 21,376 10,813 49,967 20,476 Total Rhyz Investments 73,149 60,527 203,515 151,508 Total $ 430,145 $ 498,772 $ 1,286,532 $ 1,480,491 (1) The .
Segment Contribution	Segment Contribution Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 15,881 $ 16,627 $ 48,236 $ 61,730 Southeast Asia/Pacific 9,997 13,190 31,787 37,057 Mainland China 7,277 15,223 32,903 48,192 Japan 13,491 14,617 37,201 40,033 South Korea 14,283 19,433 39,789 60,399 Europe & Africa 5,193 6,562 13,874 15,145 Hong Kong/Taiwan 9,225 10,146 25,006 28,128 Nu Skin contribution 75,347 95,798 228,796 290,684 Rhyz Investments Manufacturing 542 4,838 4,266 7,683 Rhyz other (2,923 ) (5,966 ) (14,338 ) (11,318 ) Rhyz Investments contribution (2,381 ) (1,128 ) (10,072 ) (3,635 ) Total segment contribution 72,966 94,670 218,724 287,049 Corporate and other (54,735 ) (121,035 ) (317,228 ) (254,844 ) Operating income 18,231 (26,365 ) (98,504 ) 32,205 Interest expense 6,500 7,535 20,545 18,192 Other income, net 1,567 (551 ) 1,800 3,237 Income (loss) before provision for income taxes $ 13,298 $ (34,451 ) $ (117,249 ) $ 17,250
Depreciation and Amortization and Capital Expenditures	Depreciation and Amortization Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 85 $ 115 $ 283 $ 307 Southeast Asia/Pacific 227 257 650 813 Mainland China 2,697 2,742 8,197 8,127 Japan 65 93 217 1,241 South Korea 256 310 762 1,062 Europe & Africa 283 271 830 810 Hong Kong/Taiwan 451 715 1,348 1,990 Total Nu Skin 4,064 4,503 12,287 14,350 Rhyz Investments Manufacturing 3,460 3,297 10,227 10,050 Rhyz other 1,679 2,048 5,531 3,816 Total Rhyz Investments 5,139 5,345 15,758 13,866 Corporate and other 8,118 8,344 25,316 24,123 Total $ 17,321 $ 18,192 $ 53,361 $ 52,339 Capital Expenditures Three Months Ended September 30, Nine Months Ended September 30, (U.S. dollars in thousands) 2024 2023 2024 2023 Nu Skin Americas $ 38 $ 18 $ 71 $ 209 Southeast Asia/Pacific 7 130 25 321 Mainland China 690 3,496 4,957 12,265 Japan 101 81 122 84 South Korea 7 361 29 522 Europe & Africa 97 46 386 322 Hong Kong/Taiwan 174 90 410 698 Total Nu Skin 1,114 4,222 6,000 14,421 Rhyz Investments Manufacturing 1,209 2,621 3,673 8,318 Rhyz other 490 20 1,559 20 Total Rhyz Investments 1,699 2,641 5,232 8,338 Corporate and other 5,783 5,043 17,768 15,346 Total $ 8,596 $ 11,906 $ 29,000 $ 38,105

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2024
2022 Plan [Member]
Restructuring [Abstract]
Restructuring Expense by Segment	Restructuring expense by segment - 2022 Plan (U.S. dollars in thousands) Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total Nu Skin Americas $ 918 $ 1,687 $ 2,605 Southeast Asia/Pacific 131 1,809 1,940 Mainland China 1,352 13,181 14,533 Japan 1,515 699 2,214 South Korea 422 1,533 1,955 Europe & Africa (113 ) 2,143 2,030 Hong Kong/Taiwan (201 ) 2,464 2,263 Total Nu Skin 4,024 23,516 27,540 Rhyz Investments Manufacturing 13 401 414 Rhyz other — — — Total Rhyz Investments 13 401 414 Corporate and other 5,750 19,577 25,327 Total $ 9,787 $ 43,494 $ 53,281
2023 Plan [Member]
Restructuring [Abstract]
Restructuring Expense by Segment	R Three Months Ended (U.S. dollars in thousands) June 30, 2024 March 31, 2024 December 31, 2023 Total Nu Skin Americas $ 267 $ 3,145 $ 598 $ 4,010 Southeast Asia/Pacific 190 307 862 1,359 Mainland China (162 ) 1,017 2,910 3,765 Japan — 24 — 24 South Korea (134 ) 134 — — Europe & Africa 414 677 554 1,645 Hong Kong/Taiwan (147 ) 357 432 642 Total Nu Skin 428 5,661 5,356 11,445 Rhyz Investments Manufacturing — — — — Rhyz other 40 — — 40 Total Rhyz Investments 40 — — 40 Corporate and other 7,896 1,473 4,647 14,016 Total $ 8,364 $ 7,134 $ 10,003 $ 25,501

The Company (Details)

The Company (Details)	9 Months Ended
	Sep. 30, 2024 Segment
The Company [Abstract]
Number of reportable segments	9
Number of geographic segments	7
Number of Rhyz segments	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies, Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Interest Expense [Abstract]
Interest expense	$ 6,500	$ 7,535	$ 20,545	$ 18,192
Reclassification [Member] | Other Income (Expense), Net [Member]
Interest Expense [Abstract]
Interest expense		(7,500)		(18,200)
Reclassification [Member] | Interest Expense [Member]
Interest Expense [Abstract]
Interest expense		$ 7,500		$ 18,200

Summary of Significant Accoun_5

Summary of Significant Accounting Policies, Inventory (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Inventories [Abstract]
Raw materials	$ 129,459		$ 129,459		$ 140,133
Finished goods	118,330		118,330		139,845
Total Inventory, net	247,789		247,789		$ 279,978
Valuation Allowance [Roll Forward]
Beginning balance	70,283	$ 41,017	83,378	$ 37,267
Additions	1,584	68,563	5,104	83,642
Write-offs	(8,359)	(7,347)	(24,974)	(18,676)
Ending balance	$ 63,508	$ 102,233	$ 63,508	$ 102,233

Summary of Significant Accoun_6

Summary of Significant Accounting Policies, Revenue Recognition (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Contract Liabilities - Customer Loyalty Programs [Abstract]
Contract liabilities for customer loyalty programs	$ 11.5		$ 11.5		$ 12.6
Contract liabilities, increase to revenue	$ 0.3	$ 0.8	$ 1.1	$ 6.8

Goodwill and Intangibles (Detai

Goodwill and Intangibles (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) ReportingUnit	Dec. 31, 2023 USD ($)
Goodwill and Intangibles [Abstract]
Goodwill	$ 99,885		$ 99,885	$ 230,768
Impairment of goodwill	$ 0	$ 130,900
Manufacturing and Rhyz Other Reporting Units [Member] | Minimum [Member]
Goodwill and Intangibles [Abstract]
Percentage of fair value in excess of carrying amount	2%		2%
Manufacturing and Rhyz Other Reporting Units [Member] | Maximum [Member]
Goodwill and Intangibles [Abstract]
Percentage of fair value in excess of carrying amount	8%		8%
Americas [Member]
Goodwill and Intangibles [Abstract]
Goodwill	$ 0		$ 0	9,449
Impairment of goodwill		9,400
Accumulated impairment charges	9,400		9,400	0
Southeast Asia/Pacific [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	18,537
Impairment of goodwill		18,500
Accumulated impairment charges	18,500		18,500	0
Mainland China [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	32,179
Impairment of goodwill		32,200
Accumulated impairment charges	32,200		32,200	0
Japan [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	16,019
Impairment of goodwill		16,000
Accumulated impairment charges	16,000		16,000	0
South Korea [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	29,261
Impairment of goodwill		29,300
Accumulated impairment charges	29,300		29,300	0
Europe & Africa [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	2,875
Impairment of goodwill		2,900
Accumulated impairment charges	2,900		2,900	0
Hong Kong/Taiwan [Member]
Goodwill and Intangibles [Abstract]
Goodwill	0		0	6,634
Impairment of goodwill		6,600
Accumulated impairment charges	6,600		6,600	0
Manufacturing [Member]
Goodwill and Intangibles [Abstract]
Goodwill	78,875		$ 78,875	78,875
Rhyz Other [Member]
Goodwill and Intangibles [Abstract]
Number of reporting units | ReportingUnit			3
Goodwill	21,010		$ 21,010	36,939
Accumulated impairment charges	15,900		15,900
Impairment of intangible assets		10,100
Rhyz Other [Member] | BeautyBio Retail Asset Group [Member]
Goodwill and Intangibles [Abstract]
Remaining carrying value	$ 2,300		$ 2,300
Remaining amortization period	9 years		9 years
Rhyz Other [Member] | Reporting Unit 1 [Member]
Goodwill and Intangibles [Abstract]
Goodwill	$ 12,600		$ 12,600	12,600
Rhyz Other [Member] | Reporting Unit 2 [Member]
Goodwill and Intangibles [Abstract]
Goodwill	3,700		3,700	19,600
Rhyz Other [Member] | Reporting Unit 3 [Member]
Goodwill and Intangibles [Abstract]
Goodwill	$ 4,700		$ 4,700	4,700
Rhyz Other [Member] | BeautyBio Reporting Unit [Member]
Goodwill and Intangibles [Abstract]
Impairment of goodwill		$ 15,900
Accumulated impairment charges				$ 0

Debt, Credit Agreement (Details

Debt, Credit Agreement (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Jun. 14, 2022
Credit Agreement [Member]
Debt [Abstract]
Percentage of capital stock of certain foreign subsidiaries pledged as collateral	65%
Credit Agreement [Member] | Minimum [Member]
Debt [Abstract]
Commitment fee percentage payable on unused portion	0.175%
Consolidated interest coverage ratio	3
Credit Agreement [Member] | Maximum [Member]
Debt [Abstract]
Commitment fee percentage payable on unused portion	0.30%
Consolidated leverage ratio	2.75
Term Loan Facility [Member]
Debt [Abstract]
Original principal amount	$ 400	$ 400
Term of loan	5 years
Term Loan Facility [Member] | First Year [Member]
Debt [Abstract]
Annual amortization percentage	2.50%
Term Loan Facility [Member] | Second Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Third Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Fourth Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Term Loan Facility [Member] | Fifth Year [Member]
Debt [Abstract]
Annual amortization percentage	5%
Revolving Credit Facility [Member]
Debt [Abstract]
Borrowing capacity		$ 500
Term of loan	5 years

Debt, Debt Facilities (Details)

Debt, Debt Facilities (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2024	Dec. 31, 2023	Jun. 14, 2022
Debt [Abstract]
Term of variable rate		30 days
Current portion of long-term debt		$ 60,000	$ 25,000
Credit Agreement [Member]
Debt [Abstract]
Unamortized debt issuance costs		1,500	2,000
Credit Agreement Term Loan Facility [Member]
Debt [Abstract]
Original principal amount		400,000		$ 400,000
Balance	[1],[2]	$ 365,000	385,000
Interest rate		Variable 30 day: 7.20%
Interest rate		7.20%
Term of variable rate		30 days
Repayment terms		21% of the principal amount is payable in increasing quarterly installments over a five-year period that began on September 30, 2022, with the remainder payable at the end of the five-year term.
Percentage of principal payable in installments		21%
Term of loan		5 years
Current portion of long-term debt		$ 20,000	25,000
Credit Agreement Revolving Credit Facility [Member]
Debt [Abstract]
Balance	[1],[2]	$ 70,000	120,000
Interest rate		Variable 30 day: 7.20%
Interest rate		7.20%
Term of variable rate		30 days
Repayment terms		Revolving line of credit expires June 14, 2027.
Term of loan		5 years
Current portion of long-term debt		$ 40,000	$ 0
[1] The carrying value of the debt reflects the amounts stated in the above table, less debt issuance costs of $1.5 million and $ million as of and December 31, 2023, respectively, related to the Credit Agreement, which are not reflected in this table.

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Weighted-average remaining lease term for operating leases	6 years 10 months 24 days		6 years 10 months 24 days
Weighted-average remaining lease term for finance leases	3 years 1 month 6 days		3 years 1 month 6 days
Weighted-average discount rate for operating leases	3.60%		3.60%
Weighted-average discount rate for finance leases	3.70%		3.70%
Operating Lease Expense [Abstract]
Operating lease cost	$ 5,953	$ 6,762	$ 17,892	$ 22,945
Variable lease cost	1,961	1,923	4,701	3,410
Finance Lease Expense [Abstract]
Amortization of right-of-use assets	700	1,240	2,183	3,843
Interest on lease liabilities	86	123	289	380
Total lease expense	8,700	$ 10,048	25,065	30,578
Supplemental Cash Flow Information Related to Leases [Abstract]
Operating cash outflow from operating leases			19,103	21,975
Operating cash outflow from finance leases			295	360
Financing cash outflow from finance leases			2,302	2,382
Right-of-use assets obtained in exchange for operating lease obligations			14,914	14,351
Right-of-use assets obtained in exchange for finance lease obligations			10	$ 782
Maturities of Operating Lease Liabilities [Abstract]
2024	6,371		6,371
2025	21,164		21,164
2026	16,202		16,202
2027	12,304		12,304
2028	9,112		9,112
Thereafter	32,953		32,953
Total	98,106		98,106
Less: Finance charges	10,072		10,072
Total principal liability	88,034		88,034
Maturities of Financing Lease Liabilities [Abstract]
2024	733		733
2025	2,822		2,822
2026	2,817		2,817
2027	2,795		2,795
2028	736		736
Thereafter	0		0
Total	9,903		9,903
Less: Finance charges	612		612
Total principal liability	9,291		9,291
Additional lease liabilities not yet commenced	$ 100		$ 100

Capital Stock, Net Income per S

Capital Stock, Net Income per Share (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock Awards and Options [Member]
Net Income per Share [Abstract]
Anti-dilutive shares excluded from calculation of diluted earnings per share (in shares)	2.3	2.1	1.5	1.3

Capital Stock, Dividends (Detai

Capital Stock, Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			9 Months Ended
	Nov. 07, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
Dividends per Share [Abstract]
Payment of cash dividends					$ 8,944	$ 58,353
Q1-2024 Quarterly Dividend [Member]
Dividends per Share [Abstract]
Dividend payable, date declared		2024-02			2024-02
Dividend payable per share (in dollars per share)				$ 0.06
Payment of cash dividends				$ 3,000
Dividend payable, date paid					Mar. 06, 2024
Dividend payable, date of record					Feb. 26, 2024
Q2-2024 Quarterly Dividend [Member]
Dividends per Share [Abstract]
Dividend payable, date declared		2024-05			2024-05
Dividend payable per share (in dollars per share)			$ 0.06
Payment of cash dividends			$ 3,000
Dividend payable, date paid					Jun. 12, 2024
Dividend payable, date of record					May 31, 2024
Q3-2024 Quarterly Dividend [Member]
Dividends per Share [Abstract]
Dividend payable, date declared		2024-08			2024-08
Dividend payable per share (in dollars per share)		$ 0.06
Payment of cash dividends		$ 3,000
Dividend payable, date paid					Sep. 11, 2024
Dividend payable, date of record					Aug. 30, 2024
Q4-2024 Quarterly Dividend [Member] | Subsequent Event [Member]
Dividends per Share [Abstract]
Dividend payable, date declared	2024-11
Dividend payable per share (in dollars per share)	$ 0.06
Dividend payable, date paid	Dec. 11, 2024
Dividend payable, date of record	Nov. 29, 2024

Capital Stock, Repurchase of Co

Capital Stock, Repurchase of Common Stock (Details) shares in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($) shares	Sep. 30, 2024 USD ($) shares
Repurchases of Common Stock [Abstract]
Amount available for repurchases | $	$ 162.4	$ 162.4
Treasury Stock [Member]
Repurchases of Common Stock [Abstract]
Class A common stock repurchased (in shares) | shares	0	0

Fair Value and Equity Investm_3

Fair Value and Equity Investments, Fair Value (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value and Equity Investments [Abstract]
Term of variable rate	30 days
Fair Value on a Recurring Basis [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	$ 29,539		$ 42,916
Derivative financial instruments asset	6,258		12,689
Life insurance contracts	43,994		45,041
Contingent consideration	0		(6,300)
Financial assets (liabilities)	79,791		94,346
Fair Value on a Recurring Basis [Member] | Level 1 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	29,539		42,916
Derivative financial instruments asset	0		0
Life insurance contracts	0		0
Contingent consideration	0		0
Financial assets (liabilities)	29,539		42,916
Fair Value on a Recurring Basis [Member] | Level 2 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	0		0
Derivative financial instruments asset	6,258		12,689
Life insurance contracts	0		0
Contingent consideration	0		0
Financial assets (liabilities)	6,258		12,689
Fair Value on a Recurring Basis [Member] | Level 3 [Member]
Financial Assets (Liabilities) [Abstract]
Cash equivalents and current investments	0		0
Derivative financial instruments asset	0		0
Life insurance contracts	43,994		45,041
Contingent consideration	0		(6,300)
Financial assets (liabilities)	43,994		$ 38,741
Contingent Consideration [Member]
Changes in Fair Value of Level 3 Contingent Consideration [Roll Forward]
Beginning balance	(6,300)	$ (6,364)
Changes in fair value of contingent consideration	0	(58)
Payments	6,300	0
Ending balance	0	(6,422)
Life Insurance Contracts [Member]
Changes in Fair Value of Level 3 Marketable Securities [Roll Forward]
Beginning balance	45,041	40,055
Actual return on plan assets	6,153	2,341
Sales and settlements	(7,200)	(483)
Ending balance	$ 43,994	$ 41,913

Fair Value and Equity Investm_4

Fair Value and Equity Investments, Equity Investments (Details) - Equity Securities [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2024	Dec. 31, 2023
Equity Investments [Abstract]
Carrying amount of equity securities without readily determinable fair values		$ 28.1	$ 28.1
Other Income (Expense), Net [Member]
Equity Investments [Abstract]
Upward fair value adjustments on equity securities	$ 18.1

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Income Taxes [Abstract]
Provision for income taxes	$ 4,996	$ 2,504	$ (6,760)	$ 15,937
Effective tax rate	37.60%	(7.30%)	5.80%	92.40%
Net deferred tax assets	$ 115,300		$ 115,300		$ 105,000
Undistributed earnings of non-U.S. subsidiaries					60,000
Incremental taxes if undistributed earnings on non-U.S. subsidiaries were repatriated					$ 6,000
Minimum [Member]
Income Taxes [Abstract]
Decrease in unrecognized tax benefits within the next 12 months that is reasonably possible	3,000		3,000
Maximum [Member]
Income Taxes [Abstract]
Decrease in unrecognized tax benefits within the next 12 months that is reasonably possible	$ 4,000		$ 4,000
Foreign Jurisdictions [Member] | Minimum [Member]
Income Taxes [Abstract]
Statute of limitations related to income tax examinations			3 years
Foreign Jurisdictions [Member] | Maximum [Member]
Income Taxes [Abstract]
Statute of limitations related to income tax examinations			10 years

Derivatives and Hedging Activ_3

Derivatives and Hedging Activities, Fair Value of Derivative Instruments on the Balance Sheet (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) Derivatives	Dec. 31, 2023 USD ($) Derivatives
Derivatives and Hedging Activities [Abstract]
Loss to be reclassified to interest expense during next twelve months	$ (6,300)
Number of outstanding derivatives held | Derivatives	4	4
Notional amount	$ 200,000	$ 200,000
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Prepaid Expenses and Other [Member]
Derivatives and Hedging Activities [Abstract]
Fair value, asset	6,258	8,955
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives and Hedging Activities [Abstract]
Fair value, asset	$ 0	$ 3,734

Derivatives and Hedging Activ_4

Derivatives and Hedging Activities, Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss (Details) - Interest Rate Swaps [Member] - Designated as Hedging Instrument [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other Expense, Net [Member]
Derivatives and Hedging Activities [Abstract]
Gain reclassified from accumulated other comprehensive loss into income	$ 2,655	$ 2,628	$ 7,934	$ 7,291
Other Comprehensive Loss [Member]
Derivatives and Hedging Activities [Abstract]
Gain (loss) recognized in other comprehensive loss	$ (1,211)	$ 1,515	$ 1,503	$ 4,573

Segment Information, Revenue by

Segment Information, Revenue by Segment (Details) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment	Sep. 30, 2023 USD ($)
Segment Information [Abstract]
Number of reportable segments | Segment				9
Number of geographic segments | Segment				7
Number of Rhyz segments | Segment				2
Revenue by Segment [Abstract]
Revenue		$ 430,145	$ 498,772	$ 1,286,532	$ 1,480,491
Operating Segment [Member] | Nu Skin [Member]
Revenue by Segment [Abstract]
Revenue		356,996	438,245	1,083,017	1,328,983
Operating Segment [Member] | Americas [Member]
Revenue by Segment [Abstract]
Revenue		77,194	91,671	237,160	300,469
Operating Segment [Member] | Southeast Asia/Pacific [Member]
Revenue by Segment [Abstract]
Revenue		59,515	68,743	179,921	200,317
Operating Segment [Member] | Mainland China [Member]
Revenue by Segment [Abstract]
Revenue		53,020	70,225	178,797	226,563
Operating Segment [Member] | Japan [Member]
Revenue by Segment [Abstract]
Revenue		47,222	53,399	134,045	156,867
Operating Segment [Member] | South Korea [Member]
Revenue by Segment [Abstract]
Revenue		45,201	63,709	130,283	187,719
Operating Segment [Member] | Europe & Africa [Member]
Revenue by Segment [Abstract]
Revenue		38,577	50,048	121,564	144,460
Operating Segment [Member] | Hong Kong/Taiwan [Member]
Revenue by Segment [Abstract]
Revenue		33,749	40,724	98,061	112,380
Operating Segment [Member] | Other [Member]
Revenue by Segment [Abstract]
Revenue		2,518	(274)	3,186	208
Operating Segment [Member] | Rhyz Investments [Member]
Revenue by Segment [Abstract]
Revenue		73,149	60,527	203,515	151,508
Operating Segment [Member] | Manufacturing [Member]
Revenue by Segment [Abstract]
Revenue	[1]	51,773	49,714	153,548	131,032
Operating Segment [Member] | Rhyz Other [Member]
Revenue by Segment [Abstract]
Revenue		21,376	10,813	49,967	20,476
Intersegment [Member] | Manufacturing [Member]
Revenue by Segment [Abstract]
Revenue		$ 10,900	$ 16,200	$ 28,500	$ 44,300
[1] The .

Segment Information, Segment Co

Segment Information, Segment Contribution (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Contribution [Abstract]
Operating income	$ 18,231	$ (26,365)	$ (98,504)	$ 32,205
Interest expense	6,500	7,535	20,545	18,192
Other income (expense), net	1,567	(551)	1,800	3,237
Income (loss) before provision for income taxes	13,298	(34,451)	(117,249)	17,250
Operating Segment [Member]
Segment Contribution [Abstract]
Operating income	72,966	94,670	218,724	287,049
Operating Segment [Member] | Nu Skin [Member]
Segment Contribution [Abstract]
Operating income	75,347	95,798	228,796	290,684
Operating Segment [Member] | Americas [Member]
Segment Contribution [Abstract]
Operating income	15,881	16,627	48,236	61,730
Operating Segment [Member] | Southeast Asia/Pacific [Member]
Segment Contribution [Abstract]
Operating income	9,997	13,190	31,787	37,057
Operating Segment [Member] | Mainland China [Member]
Segment Contribution [Abstract]
Operating income	7,277	15,223	32,903	48,192
Operating Segment [Member] | Japan [Member]
Segment Contribution [Abstract]
Operating income	13,491	14,617	37,201	40,033
Operating Segment [Member] | South Korea [Member]
Segment Contribution [Abstract]
Operating income	14,283	19,433	39,789	60,399
Operating Segment [Member] | Europe & Africa [Member]
Segment Contribution [Abstract]
Operating income	5,193	6,562	13,874	15,145
Operating Segment [Member] | Hong Kong/Taiwan [Member]
Segment Contribution [Abstract]
Operating income	9,225	10,146	25,006	28,128
Operating Segment [Member] | Rhyz Investments [Member]
Segment Contribution [Abstract]
Operating income	(2,381)	(1,128)	(10,072)	(3,635)
Operating Segment [Member] | Manufacturing [Member]
Segment Contribution [Abstract]
Operating income	542	4,838	4,266	7,683
Operating Segment [Member] | Rhyz Other [Member]
Segment Contribution [Abstract]
Operating income	(2,923)	(5,966)	(14,338)	(11,318)
Corporate and Other [Member]
Segment Contribution [Abstract]
Operating income	$ (54,735)	$ (121,035)	$ (317,228)	$ (254,844)

Segment Information, Depreciati

Segment Information, Depreciation and Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Summarized Financial Information [Abstract]
Depreciation and amortization	$ 17,321	$ 18,192	$ 53,361	$ 52,339
Capital expenditures	8,596	11,906	29,000	38,105
Operating Segment [Member] | Nu Skin [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	4,064	4,503	12,287	14,350
Capital expenditures	1,114	4,222	6,000	14,421
Operating Segment [Member] | Americas [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	85	115	283	307
Capital expenditures	38	18	71	209
Operating Segment [Member] | Southeast Asia/Pacific [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	227	257	650	813
Capital expenditures	7	130	25	321
Operating Segment [Member] | Mainland China [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	2,697	2,742	8,197	8,127
Capital expenditures	690	3,496	4,957	12,265
Operating Segment [Member] | Japan [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	65	93	217	1,241
Capital expenditures	101	81	122	84
Operating Segment [Member] | South Korea [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	256	310	762	1,062
Capital expenditures	7	361	29	522
Operating Segment [Member] | Europe & Africa [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	283	271	830	810
Capital expenditures	97	46	386	322
Operating Segment [Member] | Hong Kong/Taiwan [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	451	715	1,348	1,990
Capital expenditures	174	90	410	698
Operating Segment [Member] | Rhyz Investments [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	5,139	5,345	15,758	13,866
Capital expenditures	1,699	2,641	5,232	8,338
Operating Segment [Member] | Manufacturing [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	3,460	3,297	10,227	10,050
Capital expenditures	1,209	2,621	3,673	8,318
Operating Segment [Member] | Rhyz Other [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	1,679	2,048	5,531	3,816
Capital expenditures	490	20	1,559	20
Corporate and Other [Member]
Summarized Financial Information [Abstract]
Depreciation and amortization	8,118	8,344	25,316	24,123
Capital expenditures	$ 5,783	$ 5,043	$ 17,768	$ 15,346

Acquisitions, LifeDNA (Details)

Acquisitions, LifeDNA (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2023	Dec. 31, 2023	Sep. 30, 2024
Fair Value of Assets Acquired [Abstract]
Goodwill		$ 230,768	$ 99,885
LifeDNA [Member]
Acquisitions [Abstract]
Percentage interest acquired	60%
Consideration paid, cash	$ 4,000
Consideration paid, conversion of previous SAFE	3,000
Consideration paid, convertible note	200
Gross purchase price	12,000
Fair Value of Assets Acquired [Abstract]
Intangible assets	7,300
Cash	1,700
Current assets	100
Accrued liabilities	900
Deferred tax liability	900
Goodwill	4,700
Measurement period adjustments to deferred tax liability and goodwill		$ 1,100
LifeDNA [Member] | Customer Relationships [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	600
Useful life			2 years
LifeDNA [Member] | Technology [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	1,700
Useful life			7 years
LifeDNA [Member] | Tradenames [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	1,000
Useful life			7 years
LifeDNA [Member] | Other Intangibles [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	$ 4,100
Useful life			7 years

Acquisitions, BeautyBio (Detail

Acquisitions, BeautyBio (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2023	Dec. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Acquisitions [Abstract]
Purchase price, net of cash acquired			$ 0	$ 77,275
Fair Value of Assets Acquired [Abstract]
Goodwill		$ 230,768	$ 99,885
BeautyBio [Member]
Acquisitions [Abstract]
Percentage interest acquired	100%
Purchase price, net of cash acquired	$ 75,000
Cash acquired	1,500
Gross purchase price	76,500
Fair Value of Assets Acquired [Abstract]
Intangible assets	43,000
Cash	1,500
Accounts receivable	3,500
Inventory	10,300
Prepaid and other assets	800
Fixed assets	1,000
ROU operating lease asset	1,200
Lease liability	1,200
Accounts payable and accrued liabilities	2,500
Deferred tax liability	700
Goodwill	19,600
Measurement period adjustment to accounts receivable		(1,200)
Measurement period adjustment to inventory		(700)
Measurement period adjustment to accrued liabilities		(500)
Measurement period adjustment to deferred tax liability		700
Measurement period adjustment to intangible assets		(300)
Measurement period adjustment to goodwill		$ 2,400
BeautyBio [Member] | Customer Relationships [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	18,400
Useful life			9 years
BeautyBio [Member] | Technology [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	2,300
Useful life			19 years
BeautyBio [Member] | Tradenames [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	20,900
Useful life			19 years
BeautyBio [Member] | Other Intangibles [Member]
Fair Value of Assets Acquired [Abstract]
Intangible assets	$ 1,400
Useful life			3 years

Acquisitions, Revenue and Pro F

Acquisitions, Revenue and Pro Forma Revenue (Details) - LifeDNA and BeautyBio [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Acquisitions [Abstract]
Unaudited pro forma revenue as if acquisitions occurred on January 1, 2023			$ 1,489.1
Rhyz Other [Member]
Acquisitions [Abstract]
Revenue since acquisitions	$ 3	$ 12.6

Restructuring, 2022 Plan (Detai

Restructuring, 2022 Plan (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended		15 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Restructuring [Abstract]
Restructuring expense	$ 0		$ 0		$ 156,484	$ 9,787
Rhyz Other [Member]
Restructuring [Abstract]
Impairment of other intangible assets		$ 10,100
2022 Plan [Member]
Restructuring [Abstract]
Cash restructuring charges									$ 40,800
Non-cash restructuring charges									12,500
Severance charges				$ 4,000			$ 4,000	$ 20,100
Lease termination cost				1,900			1,900	7,400
Other associated restructuring costs				2,200			2,200	5,200
Impairment of fixed assets								8,200
Accelerated depreciation				1,700			1,700	900
Impairment of other intangible assets								1,700
Cash payments							19,800	21,000
Ending restructuring accrual							$ 0	11,700
Restructuring expense				9,787				43,494	53,281
2022 Plan [Member] | Nu Skin [Member]
Restructuring [Abstract]
Restructuring expense				4,024				23,516	27,540
2022 Plan [Member] | Americas [Member]
Restructuring [Abstract]
Restructuring expense				918				1,687	2,605
2022 Plan [Member] | Southeast Asia/Pacific [Member]
Restructuring [Abstract]
Restructuring expense				131				1,809	1,940
2022 Plan [Member] | Mainland China [Member]
Restructuring [Abstract]
Restructuring expense				1,352				13,181	14,533
2022 Plan [Member] | Japan [Member]
Restructuring [Abstract]
Restructuring expense				1,515				699	2,214
2022 Plan [Member] | South Korea [Member]
Restructuring [Abstract]
Restructuring expense				422				1,533	1,955
2022 Plan [Member] | Europe & Africa [Member]
Restructuring [Abstract]
Restructuring expense				(113)				2,143	2,030
2022 Plan [Member] | Hong Kong/Taiwan [Member]
Restructuring [Abstract]
Restructuring expense				(201)				2,464	2,263
2022 Plan [Member] | Rhyz Investments [Member]
Restructuring [Abstract]
Restructuring expense				13				401	414
2022 Plan [Member] | Manufacturing [Member]
Restructuring [Abstract]
Restructuring expense				13				401	414
2022 Plan [Member] | Rhyz Other [Member]
Restructuring [Abstract]
Restructuring expense				0				0	0
2022 Plan [Member] | Corporate and Other [Member]
Restructuring [Abstract]
Restructuring expense				$ 5,750				$ 19,577	$ 25,327

Restructuring, 2023 Plan (Detai

Restructuring, 2023 Plan (Details) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023
Restructuring [Abstract]
Restructuring expense	$ 0				$ 0	$ 156,484		$ 9,787
2023 Plan [Member]
Restructuring [Abstract]
Severance charges		$ 1,000	$ 4,100	$ 10,000
Other associated restructuring costs	0	100	2,000
Non-cash restructuring charges		7,200
Impairment of fixed assets		6,400	1,000
Other asset write-downs		800
Cash payments	3,900	2,800	7,000	300
Ending restructuring accrual	3,200	7,100	8,800	9,700		3,200	$ 7,100
Restructuring expense		8,364	7,134	10,003			25,501
2023 Plan [Member] | Nu Skin [Member]
Restructuring [Abstract]
Restructuring expense		428	5,661	5,356			11,445
2023 Plan [Member] | Americas [Member]
Restructuring [Abstract]
Restructuring expense		267	3,145	598			4,010
2023 Plan [Member] | Southeast Asia/Pacific [Member]
Restructuring [Abstract]
Restructuring expense		190	307	862			1,359
2023 Plan [Member] | Mainland China [Member]
Restructuring [Abstract]
Restructuring expense		(162)	1,017	2,910			3,765
2023 Plan [Member] | Japan [Member]
Restructuring [Abstract]
Restructuring expense		0	24	0			24
2023 Plan [Member] | South Korea [Member]
Restructuring [Abstract]
Restructuring expense		(134)	134	0			0
2023 Plan [Member] | Europe & Africa [Member]
Restructuring [Abstract]
Restructuring expense		414	677	554			1,645
2023 Plan [Member] | Hong Kong/Taiwan [Member]
Restructuring [Abstract]
Restructuring expense		(147)	357	432			642
2023 Plan [Member] | Rhyz Investments [Member]
Restructuring [Abstract]
Restructuring expense		40	0	0			40
2023 Plan [Member] | Manufacturing [Member]
Restructuring [Abstract]
Restructuring expense		0	0	0			0
2023 Plan [Member] | Rhyz Other [Member]
Restructuring [Abstract]
Restructuring expense		40	0	0			40
2023 Plan [Member] | Corporate and Other [Member]
Restructuring [Abstract]
Restructuring expense		$ 7,896	$ 1,473	$ 4,647			$ 14,016
2023 Plan [Member] | Severance [Member] | Minimum [Member]
Restructuring [Abstract]
Estimated charges under restructuring program	30,000					30,000
2023 Plan [Member] | Severance [Member] | Maximum [Member]
Restructuring [Abstract]
Estimated charges under restructuring program	35,000					35,000
2023 Plan [Member] | Other Cash Charges [Member]
Restructuring [Abstract]
Estimated charges under restructuring program	2,200					2,200
2023 Plan [Member] | Non-Cash Charges [Member]
Restructuring [Abstract]
Estimated charges under restructuring program	8,200					$ 8,200
2023 Plan [Member] | Fixed Asset Impairments [Member]
Restructuring [Abstract]
Impairment of fixed assets	$ 6,400